Concentra Announces Results For Its Third Quarter Ended September 30, 2026
DALLAS — November 5, 2026 — Concentra Group Holdings Parent, Inc. (“Concentra”, the “Company”, “we”, “us”, or “our”) (NYSE: CON), the nation’s largest provider of occupational health services by number of locations, today announced results for the third quarter ended September 30, 2026, declaration of a cash dividend, and raised its full-year 2026 guidance. The quarter included revenue growth of 8.6% year over year, net income attributable to the Company growth of 36.5% year over year, Adjusted EBITDA growth of 17.9% year over year, and a net leverage ratio of 2.90x.
As previously announced, effective November 1, 2026, (i) Matt DiCanio succeeded Keith Newton as president and chief executive officer, (ii) Tanner Newton became executive vice president and chief financial officer, and (iii) Keith Newton transitioned to executive chairman of the Company’s Board of Directors (the “Board”).
“Concentra delivered another strong quarter, reflecting the consistency of our operating model and the strength of our team,” said Keith Newton, executive chairman of the Board. “Over the past 50 years, we have built a market-leading occupational health company with a clear strategy for growth. With Matt assuming the CEO role, Concentra enters its next chapter with strong momentum, an experienced leadership team and significant opportunities to expand our reach and serve more employers and patients.”
“Our third-quarter results demonstrate our ability to translate strong operating performance into profitable growth,” said Matt DiCanio, president and chief executive officer. “We expanded our footprint, strengthened the balance sheet and returned capital to shareholders. The increase in full-year guidance reflects confidence in Concentra’s performance and continued momentum. Our focus remains on disciplined growth, operational excellence and delivering high- quality care while creating long-term value for customers, patients and shareholders.”
• Net income of $67.8 million, an increase of 36.0% from $49.8 million in Q3 2025
• Net income attributable to the Company of $65.9 million, and Adjusted Net Income Attributable to the Company of $66.1 million, an increase of 36.5% and 32.5% over prior year, respectively
• Earnings per share of $0.52 and Adjusted Earnings per Share of $0.52, an increase of 36.8% and 33.3% over prior year, respectively
• Adjusted EBITDA of $140.2 million an increase of 17.9% from $118.9 million in Q3 2025 • Net income margin increased to 10.9%, an expansion of 220 basis points year over year
• Adjusted EBITDA Margin increased to 22.5%, an expansion of 178 basis points year over year • Patient visits of 3,731,956, or 58,312 visits per day, an increase of 4.9% from 55,589 visits per day in Q3 2025
• Net cash provided by operating activities of $51.9 million and Free Cash Flow of $32.2 million
• Received a corporate credit rating upgrade from S&P Global, from BB- to BB, and a revised outlook from Moody’s, from stable to positive
• Total occupational health centers of 639, compared to 628 at the end of Q3 2025
• Opened three de novo occupational health centers in Kansas City, Boise, and Daytona Beach
• Completed the acquisition of a four-center occupational health practice in Minnesota
• Total onsite health clinics of 423, compared to 413 at the end of Q3 2025 1 The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release. The definition of Adjusted EBITDA Margin and a reconciliation of net income margin to Adjusted EBITDA Margin are presented in table X of this release. The definition of Adjusted Earnings per Share and a reconciliation of net income attributable to the Company and earnings per share on a fully diluted basis to Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share on a fully diluted basis are presented in table XI of this release. The definition of Free Cash Flow and a reconciliation of net cash provided by operating activities to Free Cash Flow are presented in table XII of this release.
As of September 30, 2026, our balance sheet reflected cash of $85.8 million, total debt of $1,521.3 million and total assets of $3,011.6 million. Concentra’s net leverage ratio as of September 30, 2026 was 2.90x, which was in compliance with the financial covenant under our credit agreement.
Cash flows provided by operating activities in the third quarter ended September 30, 2026 totaled $51.9 million compared to $60.6 million for the same quarter of the prior year. During the third quarter ended September 30, 2026, cash flow from investing activities resulted in cash used of $25.9 million, including capital expenditures of $22.5 million and business acquisitions of $6.2 million, partially offset by proceeds from sale of assets of $2.8 million. Concentra had Free Cash Flow of $32.2 million in the third quarter ended September 30, 2026, compared to $40.2 million for the same quarter of the prior year. Cash flow from financing activities used $98.2 million for the quarter, driven primarily by $52.4 million in repayments on the term loan, $34.7 million in repurchases of shares of common stock and $8.0 million in dividend payments. This resulted in a net decrease in cash of $72.2 million for the quarter.
On November 4, 2026, the Board declared a cash dividend of $0.0625 per share. The dividend will be payable on or about December 4, 2026, to stockholders of record as of the close of business on November 19, 2026.
There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of the Board after taking various factors into account, including, but not limited to, the Company’s financial condition, operating results, available cash and current and anticipated cash needs, the terms of indebtedness, and other factors the Board may deem to be relevant.
On November 4, 2026, the Board authorized a new share repurchase program to repurchase up to $250 million of the Company’s outstanding common stock with no expiration date (the “2026 Share Repurchase Program”). The 2026 Share Repurchase Program is in addition to the Company’s existing share repurchase program authorized in November 2025. Stock repurchases under the 2026 Share Repurchase Program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as the Board deems appropriate. The authorization of the 2026 Share Repurchase Program does not obligate the Company to repurchase any shares.
Concentra raised its financial guidance for 2026. We now expect to deliver the following results:
A reconciliation of full year 2026 Adjusted EBITDA expectations to net income is presented in table XIII of this release. A reconciliation of full year 2026 Free Cash Flow expectations to net cash provided by operating activities is presented in table XIV of this release. 2
Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America’s workforce, one patient at a time. Our approximately 13,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. We support the care of approximately 55,000 (1) patients each business day on average across 46 states and the District of Columbia at our 639 occupational health centers, 423 onsite health clinics at employer worksites, and Concentra Telemed as of September 30, 2026.
Concentra will host a conference call regarding its third quarter financial results and business outlook on Friday, November 6, 2026, at 9 a.m. Eastern Time. The conference call will be a live webcast and can be accessed via this Earnings Call Webcast Link or via Concentra’s website at https://ir.concentra.com. A replay of the webcast will be available shortly after the call at the same locations.
Participants may join the audio-only version of the webcast or participate in the question-and-answer session by calling:
International: 973-528-0011 Participant Access: All dial-in participants should ask to join the Concentra call. 3
* * * * * Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Concentra’s 2026 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:
• Adverse changes to our relationships with employer customers, third-party payors, workers’ compensation provider networks or employer services networks;
• Changes to regulations, new interpretations of existing regulations, or violations of regulations;
• State fee schedule changes undertaken by state workers’ compensation boards or commissions and other third-party payors;
• Our ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of our costs;
• Labor shortages, increased employee turnover or costs, and union activity could significantly increase our operating costs;
• Our ability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers;
• The impacts of any security breaches, cyberattacks, loss of data, or cybersecurity threats or incidents involving our, or our third-party vendors’, information technology systems, and any failure to comply with legal requirements related to data privacy, interoperability or data protection, including those governing the privacy and security of health information or other regulated, sensitive or confidential information;
• Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes;
• Significant legal actions could subject us to substantial uninsured liabilities;
• Litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our business and financial statements;
• Acquisitions may use significant resources, may be unsuccessful, and could expose us to unforeseen liabilities;
• Our exposure to additional risk due to our reliance on third parties in many aspects of our business;
• Our ability to manage relationships with managed affiliated professional medical groups;
• Our facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information;
• Compliance with applicable data interoperability and information blocking rules;
• Facility licensure requirements in some states are costly and time-consuming, limiting or delaying our operations;
• Our ability to adequately protect and enforce our intellectual property and other proprietary rights;
• Any negative impact on the global economy and capital markets resulting from geopolitical tensions;
• Our ability to maintain satisfactory credit ratings; 4 • The effects of the separation from Select Medical Corporation (“Select”) on our business;
• The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease;
• Our ability to attract and retain talented, highly skilled employees and a diverse workforce, and the succession of our senior management;
• Climate change, or legal, regulatory or market measures to address climate change;
• Increasing scrutiny and rapidly evolving expectations from stakeholders regarding ESG matters; and
Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the Securities and Exchange Commission, we are under no obligation to publicly update or revise any forward- looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in our forward- looking statements are reasonable, we cannot guarantee future results or performance.
Three Months Ended September 30, 2026 2025 % Change ────────────────────────────────────────────────────────────────────────────── Revenue $ 622,122 $ 572,800 8.6 % Costs and expenses: Cost of services, exclusive of 426,650 405,535 5.2 depreciation and amortization General and administrative, exclusive of 60,928 52,884 15.2 depreciation and amortization(1) Depreciation and 20,152 19,909 1.2 amortization Total costs and 507,730 478,328 6.1 expenses Other operating 807 — N/M income, net Income from 115,199 94,472 21.9 operations Other income and expense: Interest -25,163 -28,683 -12.3 expense Income before 90,036 65,789 36.9 income taxes Income tax 22,266 15,967 39.5 expense Net income 67,770 49,822 36.0 Less: net income attributable to 1,884 1,563 20.5 non-controlling interests Net income attributable to $ 65,886 $ 48,259 36.5 % the Company Basic and diluted earnings per $ 0.52 $ 0.38 common share:(2)
_________________________________________ (1) Includes transition services agreement fees of $0.4 million and $2.7 million for the three months ended September 30, 2026 and 2025, respectively.
N/M Not meaningful. 6 II. Condensed Consolidated Statements of Operations For the Nine Months Ended September 30, 2026 and 2025
Nine Months Ended September 30, 2026 2025 % Change ────────────────────────────────────────────────────────────────────────────── Revenue $ 1,797,707 $ 1,624,337 10.7 % Costs and expenses: Cost of services, exclusive of 1,239,669 1,151,970 7.6 depreciation and amortization General and administrat… exclusive of 172,885 152,528 13.3 depreciation and amortizatio… Depreciation and 59,699 55,526 7.5 amortization Total costs 1,472,253 1,360,024 8.3 and expenses Other operating 423 20 N/M income, net Income from 325,877 264,333 23.3 operations Other income and expense: Loss on early — -875 N/M retirement of debt Interest -76,889 -82,424 -6.7 expense Income before 248,988 181,034 37.5 income taxes Income tax 61,627 44,376 38.9 expense Net income 187,361 136,658 37.1 Less: net income attributable 5,688 4,928 15.4 to non-control… interests Net income attributable $ 181,673 $ 131,730 37.9 % to the Company Basic and diluted earnings per $ 1.42 $ 1.03 common share:(2)
_________________________________________ (1) Includes transition services agreement fees of $3.0 million and $9.9 million for the nine months ended September 30, 2026 and 2025, respectively.
(In thousands, except per share amounts, unaudited) As of September 30, 2026 and 2025, the Company’s capital structure consists of common stock and unvested restricted stock. To calculate earnings per share (“EPS”) for the three and nine months ended September 30, 2026 and 2025, the Company applied the two-class method because its unvested restricted shares were participating securities.
The following table sets forth the net income attributable to the Company, its shares, and its participating shares:
The following table sets forth the computation of EPS under the two-class method:
_________________________________________ (1) Represents the weighted average shares outstanding during the period. 8
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash $ 85,820 $ 79,899 Accounts receivable 320,258 257,900 Prepaid expenses and other current 53,581 45,299 assets Total current assets 459,659 383,098 Operating lease 557,842 483,652 right-of-use assets Property and equipment, net 240,263 225,309 Goodwill 1,482,881 1,479,192 Other identifiable intangible assets, 227,852 242,556 net Non-current deferred tax 24,754 24,120 asset Other assets 18,385 20,461 Total assets $ 3,011,636 $ 2,858,388 LIABILITIES AND EQUITY Current liabilities: Current operating lease $ 87,940 $ 84,582 liabilities Current portion of long-term debt and 11,604 10,738 notes payable Accounts payable 34,548 21,005 Accrued and other 218,885 220,922 liabilities Total current liabilities 352,977 337,247 Non-current operating lease 519,237 443,642 liabilities Long-term debt, net of 1,509,669 1,563,658 current portion Non-current deferred tax 48,633 48,906 liability Other non-current 44,355 44,506 liabilities Total liabilities 2,474,871 2,437,959 Redeemable non-controlling 22,014 19,404 interests Stockholders’ equity: Common stock, $0.01 par value, 700,000,000 shares authorized, 126,517,736 and 128,633,374 1,266 1,286 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively Capital in excess of par 200,527 248,899 Retained earnings 301,714 146,448 Accumulated other comprehensive income 3,477 -3,352 (loss) Total stockholders’ equity 506,984 393,281 Non-controlling interests 7,767 7,744 Total equity 514,751 401,025 Total liabilities and $ 3,011,636 $ 2,858,388 equity
For the Three Months Ended September 30, 2026 and 2025 (In thousands, unaudited)
Three Months Ended September 30, Operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 67,770 $ 49,822 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 20,152 19,909 amortization Stock compensation 4,546 2,330 expense Amortization of debt discount and 1,043 994 issuance costs Deferred income taxes -1,588 11,370 Other 242 -707 Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable -20,501 -7,597 Other current assets -383 2,076 Other assets -79,143 2,217 Accounts payable and 59,732 -19,787 accrued liabilities Net cash provided by operating 51,870 60,627 activities Investing activities Business combinations, net of cash -6,235 — acquired Purchases of property -22,466 -21,209 and equipment Proceeds from sale of 2,821 741 assets Net cash used in -25,880 -20,468 investing activities Financing activities Payments on revolving — -50,000 facilities Payments on term loans -52,375 -2,375 Principal payments on -1,427 -2,042 other debt Dividends paid to -7,970 -8,011 common stockholders Repurchase of common -34,650 — shares Distributions to non-controlling -1,786 -1,662 interests Net cash used in -98,208 -64,090 financing activities Net decrease in cash -72,218 -23,931 Cash at beginning of 158,038 73,872 period Cash at end of period $ 85,820 $ 49,941 Supplemental information Cash paid for interest $ 36,559 $ 39,703 Cash paid for taxes $ 31,615 $ 3,624
Nine Months Ended September 30, Operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 187,361 $ 136,658 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 59,699 55,526 amortization Loss on early — 51 retirement of debt Stock compensation 12,811 6,884 expense Amortization of debt discount and 3,115 2,965 issuance costs Deferred income taxes -3,094 9,165 Other 749 400 Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable -62,476 -33,848 Other current assets -5,569 -5,705 Other assets -75,566 4,520 Accounts payable and 91,069 -15,911 accrued liabilities Net cash provided by operating 208,099 160,705 activities Investing activities Business combinations, net of cash -9,995 -333,300 acquired Purchases of property -49,219 -62,167 and equipment Proceeds from sale of 4,291 742 assets Net cash used in -54,923 -394,725 investing activities Financing activities Borrowings on — 85,000 revolving facilities Payments on revolving — -50,000 facilities Proceeds from term loans, net of — 948,848 issuance costs Payments on term loans -57,125 -852,625 Borrowings of other 4,912 6,575 debt Principal payments on -4,976 -8,547 other debt Dividends paid to -23,979 -24,032 common stockholders Repurchase of common -60,604 — shares Distributions to non-controlling -5,483 -4,513 interests Net cash (used in) provided by financing -147,255 100,706 activities Net increase 5,921 -133,314 (decrease) in cash Cash at beginning of 79,899 183,255 period Cash at end of period $ 85,820 $ 49,941 Supplemental information Cash paid for interest $ 86,760 $ 94,135 Cash paid for taxes $ 65,999 $ 39,192
For the Three Months Ended September 30, 2026 and 2025 The following table sets forth facility counts for our occupational health centers and onsite health clinics operating segments for the periods presented:
Facility Counts Number of occupati… health centers—… of period Number of occupati… health centers acquired Number of occupati… health centers de novos Number of occupati… health centers closed Number of occupati… health centers—… of period Number of onsite health clinics—… of period The following table sets forth operating statisti… for our occupati… health centers operating segment for the periods presente… Number of patient visits Workers’ compensa… Employer services Consumer health Total 633 628 Visits 4 — per day Three 3 1 volume Months (1) (1) Workers’ Ended 639 628 compensa… September 423 413 Employer 30, 1,690,024 1,621,435 4.2 % services 2026 1,992,081 1,882,820 5.8 % Consumer Three 49,851 53,442 (6.7) % health Months 3,731,956 3,557,697 4.9 % Total Ended 26,407 25,335 4.2 % Revenue September 31,126 29,419 5.8 % per 30, 779 2025 835 (6.7) % visit(1) 2026 58,312 2025 55,589 % Change 4.9 % ────────────────────────────────────────────────────────────────────────────── Workers’ $ 219.24 $ 211.82 3.5 % compensa… Employer 95.65 92.01 4.0 % services Consumer 135.04 138.38 -2.4 % health Total $ 152.14 $ 147.31 3.3 % Business 64 64 Days(2)
(1) Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers operating segment and does not include our onsite health clinics or other businesses operating segments.
(2) Represents the number of days in which normal business operations were conducted during the periods presented. 13
For the Nine Months Ended September 30, 2026 and 2025 The following table sets forth facility counts for our occupational health centers and onsite health clinics operating segments for the periods presented:
_________________________________________ (1) Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers segment and does not include our onsite health clinics or other businesses segments.
(2) Represents the number of days in which normal business operations were conducted during the periods presented.
(In thousands, unaudited) Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP measures that we believe provide useful insight into the underlying performance of our business by excluding items that may obscure trends in our core operating results. These metrics are not intended to be substitutes for U.S. GAAP measures such as net income and net income margin, and may differ from similarly titled metrics supported by other companies. We use these non-GAAP measures internally for budgeting, forecasting, and evaluating performance. Investors should consider these measures in addition to, and not as a replacement for, U.S. GAAP results reported in our financial statements.
Adjusted EBITDA is a supplemental measure that we believe offers useful insight into the Company’s business performance by excluding items that do not reflect the core operations of the Company. We define Adjusted EBITDA as net income before interest, income taxes, depreciation and amortization, stock compensation expense, acquisition related costs, gains or losses on early retirement of debt, and separation transaction costs. We define Adjusted EBITDA Margin as Adjusted EBITDA divided by total revenue. Adjusted EBITDA Margin is a supplemental measure that we believe helps assess the efficiency of our operations on a normalized basis.
The following table reconciles net income to Adjusted EBITDA and net income margin to Adjusted EBITDA Margin and should be referenced when we discuss Adjusted EBITDA and Adjusted EBITDA Margin.
(1) The percentage of revenue values on this row represent the net income margin for the period.
(2) Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, system implementation, and software disposal costs incurred in connection with the Company’s separation from Select into a new, publicly traded company and are included within general and administrative expenses on the condensed consolidated statements of operations.
(3) The percentage of revenue values on this row represent the Adjusted EBITDA Margin for the period.
(4) Totals in this column may not foot due to rounding. 15 XI. Earnings per Share to Adjusted Earnings per Share Reconciliation
For the Three and Nine Months Ended September 30, 2026 and 2025 (In thousands, except per share amounts, unaudited)
Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share are used by management to provide useful insight into the underlying performance of our business. Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share are not measures of financial performance under U.S. GAAP and are not intended to be substitutes for U.S. GAAP measures such as net income attributable to the Company or earnings per share. These metrics may differ from similarly titled metrics supported by other companies. We believe that the presentation of Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share are important to investors because they are reflective of the financial performance of Concentra’s ongoing operations and provide better comparability of its results of operations between periods. Investors should consider these measures in addition to, and not as a replacement for, U.S. GAAP results reported in our financial statements.
We define Adjusted Net Income Attributable to the Company as net income attributable to the Company, excluding gain (loss) on early retirement of debt, separation transaction costs, and acquisition costs, all on an after tax basis. We define Adjusted Earnings per Share as the Adjusted Net Income Attributable to the Company divided by the diluted weighted average shares outstanding.
The following table reconciles net income attributable to the Company and earnings per share on a fully diluted basis to Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share on a fully diluted basis.
(1) Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, system implementation, and software disposal costs incurred in connection with the Company’s separation from Select into a new, publicly traded company and are included within general and administrative expenses on the condensed consolidated statements of operations.
(2) Tax impact is calculated using the annual effective tax rate, including discrete costs and benefits.
(3) Totals in this column may not foot due to rounding. 16 XII. Net Cash Provided by Operating Activities to Free Cash Flow Reconciliation
(In thousands, unaudited) Free Cash Flow is used by management to provide useful insight into the underlying performance of our business. Free Cash Flow is not a measure of financial performance or liquidity under U.S. GAAP and is not intended to be a substitute for U.S. GAAP measures, such as net cash provided by operating activities. This metric may differ from similarly titled metrics supported by other companies. Other companies, including companies in our industry, may calculate Free Cash Flow differently than we do, limiting the usefulness of those measures for comparative purposes. We believe that the presentation of Free Cash Flow is important to investors because it is reflective of the financial performance and cash flows of Concentra’s ongoing operations and provides a better comparability of its cash flows between periods. Investors should consider this measure in addition to, and not as a replacement for, U.S. GAAP results reporting in our financial statements.
We define Free Cash Flow as net cash provided by operating activities less net cash used in investing activities, excluding business combinations, net of cash acquired. Free Cash Flow (i) does not represent residual cash flow available for discretionary expenditures and (ii) does not reflect our mandatory debt service obligations or other non-discretionary expenditures that are not deducted in calculating the measure.
The following table reconciles net cash provided by operating activities to Free Cash Flow.
(In millions, unaudited) The following is a reconciliation of full year 2026 Adjusted EBITDA expectations as computed at the low and high points of the range to the closest comparable U.S. GAAP financial measure. Refer to table X for discussion of Concentra’s use of Adjusted EBITDA in evaluating financial performance and for the definition of Adjusted EBITDA. Each item presented in the below table is an estimation of full year 2026 expectations.
Range Low High ─────────────────────────────────────────────────────────────────── Net income attributable to the Company $ 216 $ 220 Net income attributable to 7 7 non-controlling interests Net income $ 223 $ 227 Income tax expense 74 75 Interest expense 103 103 Income from operations 400 405 Stock compensation expense 21 21 Depreciation and amortization 81 81 Separation transaction costs 3 3 Adjusted EBITDA $ 505 $ 510
18 XIV. 2026 Net Cash Provided by Operating Activities to Free Cash Flow Reconciliation
(In millions, unaudited) The following is a reconciliation of full year 2026 Free Cash Flow expectations as computed at the low and high points of the range to the closest comparable U.S. GAAP financial measure. Refer to table XII for discussion of Concentra’s use of Free Cash Flow in evaluating financial performance and for the definition of Free Cash Flow. Each item presented in the below table is an estimation of full year 2026 expectations.
Range Reconciliation of Free Cash Flow: Low High ────────────────────────────────────────────────────────────────── Net cash provided by operating $ 300 $ 310 activities Add (Subtract): Net cash used in investing activities -90 -80 Business combinations, net of cash 10 10 acquired Free Cash Flow $ 220 $ 240
Full text with the tables
NEWS RELEASE
FOR IMMEDIATE RELEASE
Concentra Announces Results For Its Third Quarter Ended September 30, 2026
and Raises FY 2026 Guidance
DALLAS — November 5, 2026 — Concentra Group Holdings Parent, Inc. (“Concentra”,
the “Company”, “we”, “us”, or “our”) (NYSE: CON), the nation’s largest provider
of occupational health services by number of locations, today announced results
for the third quarter ended September 30, 2026, declaration of a cash dividend,
and raised its full-year 2026 guidance. The quarter included revenue growth of
8.6% year over year, net income attributable to the Company growth of 36.5% year
over year, Adjusted EBITDA growth of 17.9% year over year, and a net leverage
ratio of 2.90x.
As previously announced, effective November 1, 2026, (i) Matt DiCanio succeeded
Keith Newton as president and chief executive officer, (ii) Tanner Newton became
executive vice president and chief financial officer, and (iii) Keith Newton
transitioned to executive chairman of the Company’s Board of Directors (the
“Board”).
“Concentra delivered another strong quarter, reflecting the consistency of our
operating model and the strength of our team,” said Keith Newton, executive
chairman of the Board. “Over the past 50 years, we have built a market-leading
occupational health company with a clear strategy for growth. With Matt assuming
the CEO role, Concentra enters its next chapter with strong momentum, an
experienced leadership team and significant opportunities to expand our reach
and serve more employers and patients.”
“Our third-quarter results demonstrate our ability to translate strong operating
performance into profitable growth,” said Matt DiCanio, president and chief
executive officer. “We expanded our footprint, strengthened the balance sheet
and returned capital to shareholders. The increase in full-year guidance
reflects confidence in Concentra’s performance and continued momentum. Our focus
remains on disciplined growth, operational excellence and delivering high-
quality care while creating long-term value for customers, patients and
shareholders.”
Third Quarter 2026 Highlights
• Revenue of $622.1 million, an increase of 8.6% from $572.8 million in Q3 2025
• Net income of $67.8 million, an increase of 36.0% from $49.8 million in Q3
2025
• Net income attributable to the Company of $65.9 million, and Adjusted Net
Income Attributable to the Company of $66.1 million, an increase of 36.5% and
32.5% over prior year, respectively
• Earnings per share of $0.52 and Adjusted Earnings per Share of $0.52, an
increase of 36.8% and 33.3% over prior year, respectively
• Adjusted EBITDA of $140.2 million an increase of 17.9% from $118.9 million in
Q3 2025
• Net income margin increased to 10.9%, an expansion of 220 basis points year
over year
• Adjusted EBITDA Margin increased to 22.5%, an expansion of 178 basis points
year over year
• Patient visits of 3,731,956, or 58,312 visits per day, an increase of 4.9%
from 55,589 visits per day in Q3 2025
• Revenue per visit of $152.14, an increase of 3.3% from $147.31 in Q3 2025
• Net cash provided by operating activities of $51.9 million and Free Cash Flow
of $32.2 million
• Repurchased 1.0 million shares of common stock totaling $34.65 million
• Cash balance of $85.8 million and a net leverage ratio of 2.90x
• Repaid $52.4 million on our term loan due 2031
• Received a corporate credit rating upgrade from S&P Global, from BB- to BB,
and a revised outlook from Moody’s, from stable to positive
• Total occupational health centers of 639, compared to 628 at the end of Q3
2025
• Opened three de novo occupational health centers in Kansas City, Boise, and
Daytona Beach
• Completed the acquisition of a four-center occupational health practice in
Minnesota
• Total onsite health clinics of 423, compared to 413 at the end of Q3 2025
1
The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted
EBITDA are presented in table X of this release. The definition of Adjusted
EBITDA Margin and a reconciliation of net income margin to Adjusted EBITDA
Margin are presented in table X of this release. The definition of Adjusted
Earnings per Share and a reconciliation of net income attributable to the
Company and earnings per share on a fully diluted basis to Adjusted Net Income
Attributable to the Company and Adjusted Earnings per Share on a fully diluted
basis are presented in table XI of this release. The definition of Free Cash
Flow and a reconciliation of net cash provided by operating activities to Free
Cash Flow are presented in table XII of this release.
Balance Sheet
As of September 30, 2026, our balance sheet reflected cash of $85.8 million,
total debt of $1,521.3 million and total assets of $3,011.6 million. Concentra’s
net leverage ratio as of September 30, 2026 was 2.90x, which was in compliance
with the financial covenant under our credit agreement.
Cash Flow
Cash flows provided by operating activities in the third quarter ended September
30, 2026 totaled $51.9 million compared to $60.6 million for the same quarter of
the prior year. During the third quarter ended September 30, 2026, cash flow
from investing activities resulted in cash used of $25.9 million, including
capital expenditures of $22.5 million and business acquisitions of $6.2 million,
partially offset by proceeds from sale of assets of $2.8 million. Concentra had
Free Cash Flow of $32.2 million in the third quarter ended September 30, 2026,
compared to $40.2 million for the same quarter of the prior year. Cash flow from
financing activities used $98.2 million for the quarter, driven primarily by
$52.4 million in repayments on the term loan, $34.7 million in repurchases of
shares of common stock and $8.0 million in dividend payments. This resulted in a
net decrease in cash of $72.2 million for the quarter.
Dividend
On November 4, 2026, the Board declared a cash dividend of $0.0625 per share.
The dividend will be payable on or about December 4, 2026, to stockholders of
record as of the close of business on November 19, 2026.
There is no assurance that future dividends will be declared. The declaration
and payment of dividends in the future are at the discretion of the Board after
taking various factors into account, including, but not limited to, the
Company’s financial condition, operating results, available cash and current and
anticipated cash needs, the terms of indebtedness, and other factors the Board
may deem to be relevant.
2026 Share Repurchase Program
On November 4, 2026, the Board authorized a new share repurchase program to
repurchase up to $250 million of the Company’s outstanding common stock with no
expiration date (the “2026 Share Repurchase Program”). The 2026 Share Repurchase
Program is in addition to the Company’s existing share repurchase program
authorized in November 2025. Stock repurchases under the 2026 Share Repurchase
Program may be made in the open market or through privately negotiated
transactions, and at times and in such amounts as the Board deems appropriate.
The authorization of the 2026 Share Repurchase Program does not obligate the
Company to repurchase any shares.
2026 Business Outlook
Concentra raised its financial guidance for 2026. We now expect to deliver the
following results:
• Revenue in the range of $2.360 billion to $2.380 billion
• Adjusted EBITDA in the range of $505 million to $510 million
• Free Cash Flow in the range of $220 million to $240 million
• Capital expenditures in the range of $70 million to $80 million (1)
(1) Excluding acquisitions, and net of proceeds from sale of assets.
A reconciliation of full year 2026 Adjusted EBITDA expectations to net income is
presented in table XIII of this release. A reconciliation of full year 2026 Free
Cash Flow expectations to net cash provided by operating activities is presented
in table XIV of this release.
2
Company Overview
Concentra is the largest provider of occupational health services in the United
States by number of locations, with the mission of improving the health of
America’s workforce, one patient at a time. Our approximately 13,000 colleagues
and affiliated physicians and clinicians support the delivery of an extensive
suite of services, including occupational and consumer health services and other
direct-to-employer care. We support the care of approximately 55,000 (1)
patients each business day on average across 46 states and the District of
Columbia at our 639 occupational health centers, 423 onsite health clinics at
employer worksites, and Concentra Telemed as of September 30, 2026.
(1) As of TTM September 30, 2026.
Conference Call
Concentra will host a conference call regarding its third quarter financial
results and business outlook on Friday, November 6, 2026, at 9 a.m. Eastern
Time. The conference call will be a live webcast and can be accessed via this
Earnings Call Webcast Link or via Concentra’s website at
https://ir.concentra.com. A replay of the webcast will be available shortly
after the call at the same locations.
Participants may join the audio-only version of the webcast or participate in
the question-and-answer session by calling:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access: All dial-in participants should ask to join the Concentra
call.
3
* * * * *
Certain statements contained herein that are not descriptions of historical
facts are “forward-looking” statements (as such term is defined in the Private
Securities Litigation Reform Act of 1995), including statements related to
Concentra’s 2026 and long-term business outlook. Because such statements include
risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements due to factors including
the following:
• The frequency of work-related injuries and illnesses;
• Adverse changes to our relationships with employer customers, third-party
payors, workers’ compensation provider networks or employer services networks;
• Changes to regulations, new interpretations of existing regulations, or
violations of regulations;
• State fee schedule changes undertaken by state workers’ compensation boards or
commissions and other third-party payors;
• Our ability to realize reimbursement increases at rates sufficient to keep
pace with the inflation of our costs;
• Labor shortages, increased employee turnover or costs, and union activity
could significantly increase our operating costs;
• Our ability to compete effectively with other occupational health centers,
onsite health clinics at employer worksites, and healthcare providers;
• The impacts of any security breaches, cyberattacks, loss of data, or
cybersecurity threats or incidents involving our, or our third-party vendors’,
information technology systems, and any failure to comply with legal
requirements related to data privacy, interoperability or data protection,
including those governing the privacy and security of health information or
other regulated, sensitive or confidential information;
• Negative publicity which can result in increased governmental and regulatory
scrutiny and possibly adverse regulatory changes;
• Significant legal actions could subject us to substantial uninsured
liabilities;
• Litigation and other legal and regulatory proceedings in the course of our
business that could adversely affect our business and financial statements;
• Insurance coverage may not be sufficient to cover losses we may incur;
• Acquisitions may use significant resources, may be unsuccessful, and could
expose us to unforeseen liabilities;
• Our exposure to additional risk due to our reliance on third parties in many
aspects of our business;
• Our ability to manage relationships with managed affiliated professional
medical groups;
• Our facilities are subject to extensive federal and state laws and regulations
relating to the privacy of individually identifiable information;
• Compliance with applicable data interoperability and information blocking
rules;
• Facility licensure requirements in some states are costly and time-consuming,
limiting or delaying our operations;
• Our ability to adequately protect and enforce our intellectual property and
other proprietary rights;
• Adverse economic conditions in the U.S. or globally;
• Any negative impact on the global economy and capital markets resulting from
geopolitical tensions;
• The impact of impairment of our goodwill and other intangible assets;
• Our ability to maintain satisfactory credit ratings;
4
• The effects of the separation from Select Medical Corporation (“Select”) on
our business;
• The negative impact of public threats such as a global pandemic or widespread
outbreak of an infectious disease;
• The loss of key members of our management team;
• Our ability to attract and retain talented, highly skilled employees and a
diverse workforce, and the succession of our senior management;
• Climate change, or legal, regulatory or market measures to address climate
change;
• Increasing scrutiny and rapidly evolving expectations from stakeholders
regarding ESG matters; and
• Changes in tax laws or exposures to additional tax liabilities.
Except as required by applicable law, including the securities laws of the
United States and the rules and regulations of the Securities and Exchange
Commission, we are under no obligation to publicly update or revise any forward-
looking statements, whether as a result of any new information, future events,
or otherwise. You should not place undue reliance on our forward-looking
statements. Although we believe that the expectations reflected in our forward-
looking statements are reasonable, we cannot guarantee future results or
performance.
Investor and media inquiries:
Bill Chapman
Senior Vice President, Strategy & Investor Relations
972-725-6488
[email protected]
SOURCE: Concentra Group Holdings Parent, Inc.
5
I. Condensed Consolidated Statements of Operations
For the Three Months Ended September 30, 2026 and 2025
(In thousands, except per share amounts, unaudited)
Three Months
Ended
September 30, 2026 2025 % Change
──────────────────────────────────────────────────────────────────────────────
Revenue $ 622,122 $ 572,800 8.6 %
Costs and
expenses:
Cost of
services,
exclusive of 426,650 405,535 5.2
depreciation
and
amortization
General and
administrative,
exclusive of 60,928 52,884 15.2
depreciation
and
amortization(1)
Depreciation
and 20,152 19,909 1.2
amortization
Total costs and 507,730 478,328 6.1
expenses
Other operating 807 — N/M
income, net
Income from 115,199 94,472 21.9
operations
Other income
and expense:
Interest -25,163 -28,683 -12.3
expense
Income before 90,036 65,789 36.9
income taxes
Income tax 22,266 15,967 39.5
expense
Net income 67,770 49,822 36.0
Less: net
income
attributable to 1,884 1,563 20.5
non-controlling
interests
Net income
attributable to $ 65,886 $ 48,259 36.5 %
the Company
Basic and
diluted
earnings per $ 0.52 $ 0.38
common
share:(2)
_________________________________________
(1) Includes transition services agreement fees of $0.4 million and $2.7 million
for the three months ended September 30, 2026 and 2025, respectively.
(2) Refer to table III for calculation of earnings per common share.
N/M Not meaningful.
6
II. Condensed Consolidated Statements of Operations
For the Nine Months Ended September 30, 2026 and 2025
(In thousands, except per share amounts, unaudited)
Nine Months
Ended
September 30, 2026 2025 % Change
──────────────────────────────────────────────────────────────────────────────
Revenue $ 1,797,707 $ 1,624,337 10.7 %
Costs and
expenses:
Cost of
services,
exclusive of 1,239,669 1,151,970 7.6
depreciation
and
amortization
General and
administrat…
exclusive of 172,885 152,528 13.3
depreciation
and
amortizatio…
Depreciation
and 59,699 55,526 7.5
amortization
Total costs 1,472,253 1,360,024 8.3
and expenses
Other
operating 423 20 N/M
income, net
Income from 325,877 264,333 23.3
operations
Other income
and expense:
Loss on
early — -875 N/M
retirement
of debt
Interest -76,889 -82,424 -6.7
expense
Income
before 248,988 181,034 37.5
income taxes
Income tax 61,627 44,376 38.9
expense
Net income 187,361 136,658 37.1
Less: net
income
attributable 5,688 4,928 15.4
to
non-control…
interests
Net income
attributable $ 181,673 $ 131,730 37.9 %
to the
Company
Basic and
diluted
earnings per $ 1.42 $ 1.03
common
share:(2)
_________________________________________
(1) Includes transition services agreement fees of $3.0 million and $9.9 million
for the nine months ended September 30, 2026 and 2025, respectively.
(2) Refer to table III for calculation of earnings per common share.
N/M Not meaningful.
7
III. Earnings per Share
For the Three and Nine Months Ended September 30, 2026 and 2025
(In thousands, except per share amounts, unaudited)
As of September 30, 2026 and 2025, the Company’s capital structure consists of
common stock and unvested restricted stock. To calculate earnings per share
(“EPS”) for the three and nine months ended September 30, 2026 and 2025, the
Company applied the two-class method because its unvested restricted shares were
participating securities.
The following table sets forth the net income attributable to the Company, its
shares, and its participating shares:
Three Nine
Months Months
Ended Ended
Septemb… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 67,770 $ 49,822 $ 187,361 $ 136,658
income
Less:
net
income
attrib… 1,884 1,563 5,688 4,928
to
non-co…
intere…
Net
income
attrib… 65,886 48,259 181,673 131,730
to the
Company
Less:
distri…
and
undist…
net 1,388 573 3,826 1,558
income
attrib…
to
partic…
securi…
Distri…
and
undist…
net
income $ 64,498 $ 47,686 $ 177,847 $ 130,172
attrib…
to
common
shares
The following table sets forth the computation of EPS under the two-class
method:
Th… Th…
Mo… Mo…
En… En…
Se… Se…
30, 30,
20… 20…
──────────────────────────────────────────────────────────────────────────────
Net Ba… Net Bas…
In… Sh… and In… Sha… and
Al… Di… Al… Dil…
EPS EPS
C… $ 64… 12… $ 0.… $ 47… 12… $ 0.…
s…
P… 1,… 2,… $ 0.… 573 1,… $ 0.…
s…
T… $ 65… 12… $ 0.… $ 48… 12… $ 0.…
C…
Ni… Ni…
Mo… Mo…
En… En…
Se… Se…
30, 30,
20… 20…
──────────────────────────────────────────────────────────────────────────────
Net Ba… Net Bas…
In… Sh… and In… Sha… and
Al… Di… Al… Dil…
EPS EPS
C… $ 17… 12… $ 1.… $ 13… 12… $ 1.…
s…
P… 3,… 2,… $ 1.… 1,… 1,… $ 1.…
s…
T… $ 18… 12… $ 1.… $ 13… 12… $ 1.…
C…
_________________________________________
(1) Represents the weighted average shares outstanding during the period.
8
IV. Condensed Consolidated Balance Sheets
(In thousands, except par value and share data, unaudited)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
Current assets:
Cash $ 85,820 $ 79,899
Accounts receivable 320,258 257,900
Prepaid expenses and other
current 53,581 45,299
assets
Total current assets 459,659 383,098
Operating lease 557,842 483,652
right-of-use assets
Property and equipment, net 240,263 225,309
Goodwill 1,482,881 1,479,192
Other identifiable
intangible assets, 227,852 242,556
net
Non-current deferred tax 24,754 24,120
asset
Other assets 18,385 20,461
Total assets $ 3,011,636 $ 2,858,388
LIABILITIES AND EQUITY
Current liabilities:
Current operating lease $ 87,940 $ 84,582
liabilities
Current portion of
long-term debt and 11,604 10,738
notes payable
Accounts payable 34,548 21,005
Accrued and other 218,885 220,922
liabilities
Total current liabilities 352,977 337,247
Non-current operating lease 519,237 443,642
liabilities
Long-term debt, net of 1,509,669 1,563,658
current portion
Non-current deferred tax 48,633 48,906
liability
Other non-current 44,355 44,506
liabilities
Total liabilities 2,474,871 2,437,959
Redeemable non-controlling 22,014 19,404
interests
Stockholders’ equity:
Common stock, $0.01 par
value,
700,000,000 shares
authorized,
126,517,736 and 128,633,374 1,266 1,286
shares
issued and outstanding at
September 30,
2026 and December 31, 2025,
respectively
Capital in excess of par 200,527 248,899
Retained earnings 301,714 146,448
Accumulated other
comprehensive income 3,477 -3,352
(loss)
Total stockholders’ equity 506,984 393,281
Non-controlling interests 7,767 7,744
Total equity 514,751 401,025
Total liabilities and $ 3,011,636 $ 2,858,388
equity
9
V. Condensed Consolidated Statements of Cash Flows
For the Three Months Ended September 30, 2026 and 2025
(In thousands, unaudited)
Three Months Ended
September 30,
Operating activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 67,770 $ 49,822
Adjustments to
reconcile net income to
net cash provided by
operating
activities:
Depreciation and 20,152 19,909
amortization
Stock compensation 4,546 2,330
expense
Amortization of debt
discount and 1,043 994
issuance costs
Deferred income taxes -1,588 11,370
Other 242 -707
Changes in operating
assets and
liabilities, net of
effects of business
combinations:
Accounts receivable -20,501 -7,597
Other current assets -383 2,076
Other assets -79,143 2,217
Accounts payable and 59,732 -19,787
accrued liabilities
Net cash provided by
operating 51,870 60,627
activities
Investing activities
Business combinations,
net of cash -6,235 —
acquired
Purchases of property -22,466 -21,209
and equipment
Proceeds from sale of 2,821 741
assets
Net cash used in -25,880 -20,468
investing activities
Financing activities
Payments on revolving — -50,000
facilities
Payments on term loans -52,375 -2,375
Principal payments on -1,427 -2,042
other debt
Dividends paid to -7,970 -8,011
common stockholders
Repurchase of common -34,650 —
shares
Distributions to
non-controlling -1,786 -1,662
interests
Net cash used in -98,208 -64,090
financing activities
Net decrease in cash -72,218 -23,931
Cash at beginning of 158,038 73,872
period
Cash at end of period $ 85,820 $ 49,941
Supplemental
information
Cash paid for interest $ 36,559 $ 39,703
Cash paid for taxes $ 31,615 $ 3,624
10
VI. Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2026 and 2025
(In thousands, unaudited)
Nine Months Ended
September 30,
Operating activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 187,361 $ 136,658
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Depreciation and 59,699 55,526
amortization
Loss on early — 51
retirement of debt
Stock compensation 12,811 6,884
expense
Amortization of debt
discount and 3,115 2,965
issuance costs
Deferred income taxes -3,094 9,165
Other 749 400
Changes in operating
assets and
liabilities, net of
effects of business
combinations:
Accounts receivable -62,476 -33,848
Other current assets -5,569 -5,705
Other assets -75,566 4,520
Accounts payable and 91,069 -15,911
accrued liabilities
Net cash provided by
operating 208,099 160,705
activities
Investing activities
Business combinations,
net of cash -9,995 -333,300
acquired
Purchases of property -49,219 -62,167
and equipment
Proceeds from sale of 4,291 742
assets
Net cash used in -54,923 -394,725
investing activities
Financing activities
Borrowings on — 85,000
revolving facilities
Payments on revolving — -50,000
facilities
Proceeds from term
loans, net of — 948,848
issuance costs
Payments on term loans -57,125 -852,625
Borrowings of other 4,912 6,575
debt
Principal payments on -4,976 -8,547
other debt
Dividends paid to -23,979 -24,032
common stockholders
Repurchase of common -60,604 —
shares
Distributions to
non-controlling -5,483 -4,513
interests
Net cash (used in)
provided by financing -147,255 100,706
activities
Net increase 5,921 -133,314
(decrease) in cash
Cash at beginning of 79,899 183,255
period
Cash at end of period $ 85,820 $ 49,941
Supplemental
information
Cash paid for interest $ 86,760 $ 94,135
Cash paid for taxes $ 65,999 $ 39,192
11
VII. Disaggregated Revenue
For the Three and Nine Months Ended September 30, 2026 and 2025
(In thousands, unaudited)
The following table disaggregates the Company’s revenue:
Three Nine
Months Months
Ended Ended
Occu… Septem… Septe…
heal… 30, 30,
cent… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Work… $ 370,5… $ 343,454 $ 1,069,… $ 977,7…
comp…
Empl… 190,5… 173,230 546,072 507,6…
serv…
Cons… 6,732 7,395 21,455 23,183
heal…
Other
occu…
heal… 1,882 1,953 6,145 6,469
cent…
reve…
Total
occu…
heal… 569,6… 526,032 1,643,… 1,515…
cent…
reve…
Onsi…
heal… 38,393 34,897 114,421 74,016
clin…
Other 14,056 11,871 40,195 35,229
Total $ 622,1… $ 572,800 $ 1,797,… $ 1,624…
reve…
12
VIII. Key Statistics
For the Three Months Ended September 30, 2026 and 2025
The following table sets forth facility counts for our occupational health
centers and onsite health clinics operating segments for the periods presented:
Facility
Counts
Number of
occupati…
health
centers—…
of period
Number of
occupati…
health
centers
acquired
Number of
occupati…
health
centers
de novos
Number of
occupati…
health
centers
closed
Number of
occupati…
health
centers—…
of period
Number of
onsite
health
clinics—…
of period
The
following
table
sets
forth
operating
statisti…
for our
occupati…
health
centers
operating
segment
for the
periods
presente…
Number of
patient
visits
Workers’
compensa…
Employer
services
Consumer
health
Total 633 628
Visits 4 —
per day Three 3 1
volume Months (1) (1)
Workers’ Ended 639 628
compensa… September 423 413
Employer 30, 1,690,024 1,621,435 4.2 %
services 2026 1,992,081 1,882,820 5.8 %
Consumer Three 49,851 53,442 (6.7) %
health Months 3,731,956 3,557,697 4.9 %
Total Ended 26,407 25,335 4.2 %
Revenue September 31,126 29,419 5.8 %
per 30, 779 2025 835 (6.7) %
visit(1) 2026 58,312 2025 55,589 % Change 4.9 %
──────────────────────────────────────────────────────────────────────────────
Workers’ $ 219.24 $ 211.82 3.5 %
compensa…
Employer 95.65 92.01 4.0 %
services
Consumer 135.04 138.38 -2.4 %
health
Total $ 152.14 $ 147.31 3.3 %
Business 64 64
Days(2)
_________________________________________
(1) Represents the average amount of revenue recognized for each patient visit.
Revenue per visit is calculated as total patient revenue divided by total
patient visits. Revenue per visit as reported includes only the revenue and
patient visits in our occupational health centers operating segment and does not
include our onsite health clinics or other businesses operating segments.
(2) Represents the number of days in which normal business operations were
conducted during the periods presented.
13
IX. Key Statistics
For the Nine Months Ended September 30, 2026 and 2025
The following table sets forth facility counts for our occupational health
centers and onsite health clinics operating segments for the periods presented:
Facili…
Counts
Number
of
occupa…
health
center…
of
period
Number
of
occupa…
health
centers
acquir…
Number
of
occupa…
health
centers
de
novos
Number
of
occupa…
health
centers
closed
Number
of
occupa…
health
center…
of
period
Number
of
onsite
health
clinic…
of
period
The
follow…
table
sets
forth
operat…
statis…
for our
occupa…
health
centers
operat…
segment
for the
periods
presen…
Number
of
patient
visits
Worker…
compen…
Employ…
servic…
Consum…
health
Total 628 552
Visits 7 72
per day Nine 5 5
volume Months (1) (1)
Worker… Ended 639 628
compen… Septemb… 423 413
Employ… 30, 4,922,3… 4,656,2… 5.7 %
servic… 2026 5,681,6… 5,456,6… 4.1 %
Consum… Nine 157,982 169,474 (6.8) %
health Months 10,761,… 10,282,… 4.7 %
Total Ended 25,771 24,379 5.7 %
Revenue Septemb… 29,747 28,569 4.1 %
per 30, 827 2025 887 (6.8) %
visit(… 2026 56,345 2025 53,834 (3) % Change 4.7 %
──────────────────────────────────────────────────────────────────────────────
Worker… $ 217.26 $ 209.98 3.5 %
compen…
Employ… 96.11 93.04 3.3 %
servic…
Consum… 135.81 136.80 -0.7 %
health
Total $ 152.10 $ 146.72 3.7 %
Busine… 191 191
days(2)
_________________________________________
(1) Represents the average amount of revenue recognized for each patient visit.
Revenue per visit is calculated as total patient revenue divided by total
patient visits. Revenue per visit as reported includes only the revenue and
patient visits in our occupational health centers segment and does not include
our onsite health clinics or other businesses segments.
(2) Represents the number of days in which normal business operations were
conducted during the periods presented.
(3) Does not foot due to rounding.
14
X. Net Income to Adjusted EBITDA Reconciliation
For the Three and Nine Months Ended September 30, 2026 and 2025
(In thousands, unaudited)
Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP measures that we believe
provide useful insight into the underlying performance of our business by
excluding items that may obscure trends in our core operating results. These
metrics are not intended to be substitutes for U.S. GAAP measures such as net
income and net income margin, and may differ from similarly titled metrics
supported by other companies. We use these non-GAAP measures internally for
budgeting, forecasting, and evaluating performance. Investors should consider
these measures in addition to, and not as a replacement for, U.S. GAAP results
reported in our financial statements.
Adjusted EBITDA is a supplemental measure that we believe offers useful insight
into the Company’s business performance by excluding items that do not reflect
the core operations of the Company. We define Adjusted EBITDA as net income
before interest, income taxes, depreciation and amortization, stock compensation
expense, acquisition related costs, gains or losses on early retirement of debt,
and separation transaction costs. We define Adjusted EBITDA Margin as Adjusted
EBITDA divided by total revenue. Adjusted EBITDA Margin is a supplemental
measure that we believe helps assess the efficiency of our operations on a
normalized basis.
The following table reconciles net income to Adjusted EBITDA and net income
margin to Adjusted EBITDA Margin and should be referenced when we discuss
Adjusted EBITDA and Adjusted EBITDA Margin.
… …
… …
… …
… …
… % % … % %
… … … … … … … …
… … … … … … … …
──────────────────────────────────────────────────────────────────────────────
$ … … % $ … … % $ … … % $ … … %
… … … … … … … …
… … … … … … … …
— — — — — — … …
… … … … … … … …
… … … … … … … …
… … … … … … … …
… … … … … … … …
$ … … % $ … … % $ … … % $ … … %
_________________________________________
(1) The percentage of revenue values on this row represent the net income margin
for the period.
(2) Separation transaction costs represent non-recurring incremental consulting,
legal, audit-related fees, system implementation, and software disposal costs
incurred in connection with the Company’s separation from Select into a new,
publicly traded company and are included within general and administrative
expenses on the condensed consolidated statements of operations.
(3) The percentage of revenue values on this row represent the Adjusted EBITDA
Margin for the period.
(4) Totals in this column may not foot due to rounding.
15
XI. Earnings per Share to Adjusted Earnings per Share Reconciliation
For the Three and Nine Months Ended September 30, 2026 and 2025
(In thousands, except per share amounts, unaudited)
Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share
are used by management to provide useful insight into the underlying performance
of our business. Adjusted Net Income Attributable to the Company and Adjusted
Earnings per Share are not measures of financial performance under U.S. GAAP and
are not intended to be substitutes for U.S. GAAP measures such as net income
attributable to the Company or earnings per share. These metrics may differ from
similarly titled metrics supported by other companies. We believe that the
presentation of Adjusted Net Income Attributable to the Company and Adjusted
Earnings per Share are important to investors because they are reflective of the
financial performance of Concentra’s ongoing operations and provide better
comparability of its results of operations between periods. Investors should
consider these measures in addition to, and not as a replacement for, U.S. GAAP
results reported in our financial statements.
We define Adjusted Net Income Attributable to the Company as net income
attributable to the Company, excluding gain (loss) on early retirement of debt,
separation transaction costs, and acquisition costs, all on an after tax basis.
We define Adjusted Earnings per Share as the Adjusted Net Income Attributable to
the Company divided by the diluted weighted average shares outstanding.
The following table reconciles net income attributable to the Company and
earnings per share on a fully diluted basis to Adjusted Net Income Attributable
to the Company and Adjusted Earnings per Share on a fully diluted basis.
T… …
M… …
E… …
S… …
3… … … … … …
2… … … … … … … …
──────────────────────────────────────────────────────────────────────────────
$ … $ 0… $ 4… $ 0… $ 1… $ 1… $ 1… $ 1…
— — — — — — 8… 0…
2… 0… 1… 0… 3… 0… 2… 0…
66 0… 1… 0… 3… 0… 7… 0…
$ … $ 0… $ 2… $ 0… $ 3… $ 0… $ 1… $ 0…
… -… -… -… -… -… -… -…
$ … $ 0… $ 4… $ 0… $ 1… $ 1… $ 1… $ 1…
1… 1… 1… 1…
_________________________________________
(1) Separation transaction costs represent non-recurring incremental consulting,
legal, audit-related fees, system implementation, and software disposal costs
incurred in connection with the Company’s separation from Select into a new,
publicly traded company and are included within general and administrative
expenses on the condensed consolidated statements of operations.
(2) Tax impact is calculated using the annual effective tax rate, including
discrete costs and benefits.
(3) Totals in this column may not foot due to rounding.
16
XII. Net Cash Provided by Operating Activities to Free Cash Flow Reconciliation
For the Three and Nine Months ended September 30, 2026 and 2025
(In thousands, unaudited)
Free Cash Flow is used by management to provide useful insight into the
underlying performance of our business. Free Cash Flow is not a measure of
financial performance or liquidity under U.S. GAAP and is not intended to be a
substitute for U.S. GAAP measures, such as net cash provided by operating
activities. This metric may differ from similarly titled metrics supported by
other companies. Other companies, including companies in our industry, may
calculate Free Cash Flow differently than we do, limiting the usefulness of
those measures for comparative purposes. We believe that the presentation of
Free Cash Flow is important to investors because it is reflective of the
financial performance and cash flows of Concentra’s ongoing operations and
provides a better comparability of its cash flows between periods. Investors
should consider this measure in addition to, and not as a replacement for, U.S.
GAAP results reporting in our financial statements.
We define Free Cash Flow as net cash provided by operating activities less net
cash used in investing activities, excluding business combinations, net of cash
acquired. Free Cash Flow (i) does not represent residual cash flow available for
discretionary expenditures and (ii) does not reflect our mandatory debt service
obligations or other non-discretionary expenditures that are not deducted in
calculating the measure.
The following table reconciles net cash provided by operating activities to Free
Cash Flow.
Three Nine
Reco… Months Months
of Ended Ended
Free Septem… Septe…
Cash 30, 30,
Flow: 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
prov… $ 51,870 $ 60,627 $ 208,099 $ 160,7…
by
oper…
acti…
Add
(Sub…
Net
cash
used -25,8… -20,468 -54,923 -394,…
in
inve…
acti…
Busi…
comb…
net 6,235 — 9,995 333,3…
of
cash
acqu…
Free
Cash $ 32,225 $ 40,159 $ 163,171 $ 99,280
Flow
17
XIII. 2026 Net Income to Adjusted EBITDA Reconciliation
Business Outlook for the Year Ending December 31, 2026
(In millions, unaudited)
The following is a reconciliation of full year 2026 Adjusted EBITDA expectations
as computed at the low and high points of the range to the closest comparable
U.S. GAAP financial measure. Refer to table X for discussion of Concentra’s use
of Adjusted EBITDA in evaluating financial performance and for the definition of
Adjusted EBITDA. Each item presented in the below table is an estimation of full
year 2026 expectations.
Range
Low High
───────────────────────────────────────────────────────────────────
Net income attributable to the Company $ 216 $ 220
Net income attributable to 7 7
non-controlling interests
Net income $ 223 $ 227
Income tax expense 74 75
Interest expense 103 103
Income from operations 400 405
Stock compensation expense 21 21
Depreciation and amortization 81 81
Separation transaction costs 3 3
Adjusted EBITDA $ 505 $ 510
18
XIV. 2026 Net Cash Provided by Operating Activities to Free Cash Flow
Reconciliation
Business Outlook for the Year Ending December 31, 2026
(In millions, unaudited)
The following is a reconciliation of full year 2026 Free Cash Flow expectations
as computed at the low and high points of the range to the closest comparable
U.S. GAAP financial measure. Refer to table XII for discussion of Concentra’s
use of Free Cash Flow in evaluating financial performance and for the definition
of Free Cash Flow. Each item presented in the below table is an estimation of
full year 2026 expectations.
Range
Reconciliation of Free Cash Flow: Low High
──────────────────────────────────────────────────────────────────
Net cash provided by operating $ 300 $ 310
activities
Add (Subtract):
Net cash used in investing activities -90 -80
Business combinations, net of cash 10 10
acquired
Free Cash Flow $ 220 $ 240
19